ARAnna Rea

Anna Rea

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anna Rea has a total of 53 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Figures from CD137 Costimulation Counteracts TGFβ Inhibition of NK-cell Antitumor Function

    by Mariona Cabo, Sara Santana-Hernández, Marcel Costa-Garcia, Anna Rea, Roberto Lozano-Rodríguez, Michelle Ataya, Francesc Balaguer, Manel Juan, Maria C. Ochoa, Silvia Menéndez, et al.

    Figures S1, S2, S3, S4, S5, S6

  • Open Access

    Supplementary Tables from CD137 Costimulation Counteracts TGFβ Inhibition of NK-cell Antitumor Function

    by Mariona Cabo, Sara Santana-Hernández, Marcel Costa-Garcia, Anna Rea, Roberto Lozano-Rodríguez, Michelle Ataya, Francesc Balaguer, Manel Juan, Maria C. Ochoa, Silvia Menéndez, et al.

  • Open Access

    Data from CD137 Costimulation Counteracts TGFβ Inhibition of NK-cell Antitumor Function

    by Mariona Cabo, Sara Santana-Hernández, Marcel Costa-Garcia, Anna Rea, Roberto Lozano-Rodríguez, Michelle Ataya, Francesc Balaguer, Manel Juan, Maria C. Ochoa, Silvia Menéndez, et al.

    Enhancing natural killer (NK) cell–based cancer immunotherapy by overcoming immunosuppression is an area of intensive research. Here, we have demonstrated that the anti-CD137 agonist urelumab can overcome TGFβ-mediated inhibition of human NK-cell proliferation and antitumor function. Transcriptomic, immunophenotypic, and functional analyses showed that CD137 costimulation modified the transcriptional program induced by TGFβ on human NK cells by rescuing their proliferation in response to IL2, preserving their expression of activating receptors (NKG2D) and effector molecules (granzyme B, IFNγ) while allowing the acquisition of tumor-homing/retention features (CXCR3, CD103). Activated NK cells cultured in the presence of TGFβ1 and CD137 agonist recovered CCL5 and IFNγ secretion and showed enhanced direct and antibody-dependent cytotoxicity upon restimulation with cancer cells. Trastuzumab treatment of fresh breast carcinoma–derived multicellular cultures induced CD137 expression on tumor-infiltrating CD16+ NK cells, enabling the action of urelumab, which fostered tumor-infiltrating NK cells and recapitulated the enhancement of CCL5 and IFNγ production. Bioinformatic analysis pointed to IFNG as the driver of the association between NK cells and clinical response to trastuzumab in patients with HER2-positive primary breast cancer, highlighting the translational relevance of the CD137 costimulatory axis for enhancing IFNγ production. Our data reveals CD137 as a targetable checkpoint for overturning TGFβ constraints on NK-cell antitumor responses.

  • Open Access

    Supplementary Tables from CD137 Costimulation Counteracts TGFβ Inhibition of NK-cell Antitumor Function

    by Mariona Cabo, Sara Santana-Hernández, Marcel Costa-Garcia, Anna Rea, Roberto Lozano-Rodríguez, Michelle Ataya, Francesc Balaguer, Manel Juan, Maria C. Ochoa, Silvia Menéndez, et al.

  • Open Access

    Supplementary Figures from CD137 Costimulation Counteracts TGFβ Inhibition of NK-cell Antitumor Function

    by Mariona Cabo, Sara Santana-Hernández, Marcel Costa-Garcia, Anna Rea, Roberto Lozano-Rodríguez, Michelle Ataya, Francesc Balaguer, Manel Juan, Maria C. Ochoa, Silvia Menéndez, et al.

    Figures S1, S2, S3, S4, S5, S6

  • Open Access

    Data from CD137 Costimulation Counteracts TGFβ Inhibition of NK-cell Antitumor Function

    by Mariona Cabo, Sara Santana-Hernández, Marcel Costa-Garcia, Anna Rea, Roberto Lozano-Rodríguez, Michelle Ataya, Francesc Balaguer, Manel Juan, Maria C. Ochoa, Silvia Menéndez, et al.

    Enhancing natural killer (NK) cell–based cancer immunotherapy by overcoming immunosuppression is an area of intensive research. Here, we have demonstrated that the anti-CD137 agonist urelumab can overcome TGFβ-mediated inhibition of human NK-cell proliferation and antitumor function. Transcriptomic, immunophenotypic, and functional analyses showed that CD137 costimulation modified the transcriptional program induced by TGFβ on human NK cells by rescuing their proliferation in response to IL2, preserving their expression of activating receptors (NKG2D) and effector molecules (granzyme B, IFNγ) while allowing the acquisition of tumor-homing/retention features (CXCR3, CD103). Activated NK cells cultured in the presence of TGFβ1 and CD137 agonist recovered CCL5 and IFNγ secretion and showed enhanced direct and antibody-dependent cytotoxicity upon restimulation with cancer cells. Trastuzumab treatment of fresh breast carcinoma–derived multicellular cultures induced CD137 expression on tumor-infiltrating CD16+ NK cells, enabling the action of urelumab, which fostered tumor-infiltrating NK cells and recapitulated the enhancement of CCL5 and IFNγ production. Bioinformatic analysis pointed to IFNG as the driver of the association between NK cells and clinical response to trastuzumab in patients with HER2-positive primary breast cancer, highlighting the translational relevance of the CD137 costimulatory axis for enhancing IFNγ production. Our data reveals CD137 as a targetable checkpoint for overturning TGFβ constraints on NK-cell antitumor responses.

  • Open Access

    Characterization of KIR+NK cell subsets with a monoclonal antibody selectively recognizing KIR2DL1 and blocking the specific interaction with HLA‐C

    by Raffaella Meazza, Michela Falco, Paolo Canevali, Fabrizio Loiacono, Natalia Colomar‐Carando, Aura Muntasell, Anna Rea, Maria Cristina Mingari, Franco Locatelli, Lorenzo Moretta, et al.

    The phenotypic identification of different NK cell subsets allows more in‐depth characterization of KIR repertoire and function, which are of potential interest in KIR and disease association studies. KIR genes are highly polymorphic, but a great homology exists among the various sequences and few monoclonal antibodies (mAbs) specifically recognize a single KIR. This is the case of HP‐DM1 which was demonstrated by analysis of cell transfectants and epitope mapping to be exclusively KIR2DL1‐specific, covering all allotypes identified to date, except for KIR2DL1*022 and *020, and also to react with KIR2DS1*013. Here, we compared in immunofluorescence analyses the staining of HP‐DM1 with other available mAbs to precisely identify KIR2DL1+ NK cells in potential donors for αβT/B‐depleted haplo‐HSCT, with known KIR genotype. HP‐DM1 mAb was used in combination with EB6 or 11PB6 (anti‐KIR2DL1/S1 and anti‐KIR2DL3*005), 143211 (anti‐KIR2DL1/S5), and HP‐MA4 (anti‐KIR2DL1/S1/S3/S5) mAbs, allowing the accurate identification of different KIR+ NK cell subsets. These phenotypic evaluations appeared useful to dissect the expression pattern of various KIR2D in NK cells from KIR2DL3*005+ individuals, particularly if KIR2DS1 is present. HP‐DM1 mAb remarkably refined NK cell phenotyping of donors carrying KIR2DS5, either in the centromeric or telomeric region. Functional assays with KIR2DL1+/S1+/S5+ NK cells confirmed that only HP‐DM1 exclusively reacts with KIR2DL1. Finally, we demonstrated that HP‐DM1 mAb blocked KIR2DL1 recognition of C2+ HLA‐C. Altogether, the data support that HP‐DM1 is a unique reagent valuable for characterizing KIR+ NK cell subsets.


  • CD137 Costimulation Counteracts TGFβ Inhibition of NK-cell Antitumor Function

    by Mariona Cabo, Sara Santana-Hernández, Marcel Costa-Garcia, Anna Rea, Roberto Lozano-Rodríguez, Michelle Ataya, Francesc Balaguer, Manel Juan, Maria C. Ochoa, Silvia Menéndez, et al.

    Enhancing natural killer (NK) cell–based cancer immunotherapy by overcoming immunosuppression is an area of intensive research. Here, we have demonstrated that the anti-CD137 agonist urelumab can overcome TGFβ-mediated inhibition of human NK-cell proliferation and antitumor function. Transcriptomic, immunophenotypic, and functional analyses showed that CD137 costimulation modified the transcriptional program induced by TGFβ on human NK cells by rescuing their proliferation in response to IL2, preserving their expression of activating receptors (NKG2D) and effector molecules (granzyme B, IFNγ) while allowing the acquisition of tumor-homing/retention features (CXCR3, CD103). Activated NK cells cultured in the presence of TGFβ1 and CD137 agonist recovered CCL5 and IFNγ secretion and showed enhanced direct and antibody-dependent cytotoxicity upon restimulation with cancer cells. Trastuzumab treatment of fresh breast carcinoma–derived multicellular cultures induced CD137 expression on tumor-infiltrating CD16+ NK cells, enabling the action of urelumab, which fostered tumor-infiltrating NK cells and recapitulated the enhancement of CCL5 and IFNγ production. Bioinformatic analysis pointed to IFNG as the driver of the association between NK cells and clinical response to trastuzumab in patients with HER2-positive primary breast cancer, highlighting the translational relevance of the CD137 costimulatory axis for enhancing IFNγ production. Our data reveals CD137 as a targetable checkpoint for overturning TGFβ constraints on NK-cell antitumor responses.


  • Open Access

    Epigenetic loss of m1A RNA demethylase ALKBH3 in Hodgkin lymphoma targets collagen, conferring poor clinical outcome

    by Rosaura Esteve-Puig, Fina Climent, David Piñeyro, Eva Domingo-Domènech, Veronica Davalos, Maite Encuentra, Anna Rea, Nadia Espejo-Herrera, Marta Soler, Miguel Lopez, et al.